vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Gaming & Leisure Properties, Inc. (GLPI). Click either name above to swap in a different company.
Gaming & Leisure Properties, Inc. is the larger business by last-quarter revenue ($420.0M vs $247.1M, roughly 1.7× ANI PHARMACEUTICALS INC). Gaming & Leisure Properties, Inc. runs the higher net margin — 57.0% vs 11.1%, a 45.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 6.3%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 5.0%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Gaming and Leisure Properties, Inc. is a real estate investment trust (REIT) specializing in casino properties, based in Wyomissing, Pennsylvania. It was formed in November 2013 as a corporate spin-off from Penn National Gaming. The company owns 62 casino properties, all of which are leased to other companies.
ANIP vs GLPI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $420.0M |
| Net Profit | $27.5M | $239.4M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 79.4% |
| Net Margin | 11.1% | 57.0% |
| Revenue YoY | 29.6% | 6.3% |
| Net Profit YoY | 367.5% | 40.5% |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $420.0M | ||
| Q4 25 | $247.1M | $407.0M | ||
| Q3 25 | $227.8M | $397.6M | ||
| Q2 25 | $211.4M | $394.9M | ||
| Q1 25 | $197.1M | $395.2M | ||
| Q4 24 | $190.6M | $389.6M | ||
| Q3 24 | $148.3M | $385.3M | ||
| Q2 24 | $138.0M | $380.6M |
| Q1 26 | — | $239.4M | ||
| Q4 25 | $27.5M | $275.4M | ||
| Q3 25 | $26.6M | $241.2M | ||
| Q2 25 | $8.5M | $151.4M | ||
| Q1 25 | $15.7M | $165.2M | ||
| Q4 24 | $-10.3M | $223.6M | ||
| Q3 24 | $-24.2M | $184.7M | ||
| Q2 24 | $-2.3M | $208.3M |
| Q1 26 | — | 79.4% | ||
| Q4 25 | 14.1% | 89.3% | ||
| Q3 25 | 15.9% | 84.8% | ||
| Q2 25 | 6.6% | 61.3% | ||
| Q1 25 | 13.3% | 65.5% | ||
| Q4 24 | -2.3% | 79.1% | ||
| Q3 24 | -13.8% | 70.4% | ||
| Q2 24 | 3.7% | 77.1% |
| Q1 26 | — | 57.0% | ||
| Q4 25 | 11.1% | 67.6% | ||
| Q3 25 | 11.7% | 60.7% | ||
| Q2 25 | 4.0% | 38.4% | ||
| Q1 25 | 8.0% | 41.8% | ||
| Q4 24 | -5.4% | 57.4% | ||
| Q3 24 | -16.3% | 47.9% | ||
| Q2 24 | -1.7% | 54.7% |
| Q1 26 | — | — | ||
| Q4 25 | $1.14 | $0.96 | ||
| Q3 25 | $1.13 | $0.85 | ||
| Q2 25 | $0.36 | $0.54 | ||
| Q1 25 | $0.69 | $0.60 | ||
| Q4 24 | $-0.45 | $0.79 | ||
| Q3 24 | $-1.27 | $0.67 | ||
| Q2 24 | $-0.14 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $274.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $5.0B |
| Total Assets | $1.4B | $13.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $274.5M | ||
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | $560.8M | ||
| Q3 24 | $145.0M | $560.8M | ||
| Q2 24 | $240.1M | $560.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $7.2B | ||
| Q3 25 | — | $7.2B | ||
| Q2 25 | — | $6.9B | ||
| Q1 25 | — | $6.9B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.4B | ||
| Q2 24 | — | $6.6B |
| Q1 26 | — | $5.0B | ||
| Q4 25 | $540.7M | $4.6B | ||
| Q3 25 | $505.8M | $4.6B | ||
| Q2 25 | $436.8M | $4.6B | ||
| Q1 25 | $418.6M | $4.2B | ||
| Q4 24 | $403.7M | $4.3B | ||
| Q3 24 | $405.9M | $4.3B | ||
| Q2 24 | $455.8M | $4.1B |
| Q1 26 | — | $13.8B | ||
| Q4 25 | $1.4B | $12.9B | ||
| Q3 25 | $1.4B | $12.8B | ||
| Q2 25 | $1.3B | $12.5B | ||
| Q1 25 | $1.3B | $12.1B | ||
| Q4 24 | $1.3B | $13.1B | ||
| Q3 24 | $1.3B | $12.7B | ||
| Q2 24 | $920.8M | $11.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.56× | ||
| Q3 25 | — | 1.57× | ||
| Q2 25 | — | 1.51× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | — | 1.74× | ||
| Q2 24 | — | 1.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $1.1B | ||
| Q3 25 | $44.1M | $240.3M | ||
| Q2 25 | $75.8M | $293.4M | ||
| Q1 25 | $35.0M | $252.5M | ||
| Q4 24 | $15.9M | $1.1B | ||
| Q3 24 | $12.5M | $270.4M | ||
| Q2 24 | $17.4M | $252.1M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $183.0M | ||
| Q2 25 | $71.8M | $272.3M | ||
| Q1 25 | $32.5M | $239.6M | ||
| Q4 24 | $13.5M | $1.1B | ||
| Q3 24 | $7.7M | $261.5M | ||
| Q2 24 | $13.0M | $245.0M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | 46.0% | ||
| Q2 25 | 34.0% | 69.0% | ||
| Q1 25 | 16.5% | 60.6% | ||
| Q4 24 | 7.1% | 275.3% | ||
| Q3 24 | 5.2% | 67.9% | ||
| Q2 24 | 9.4% | 64.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | 14.4% | ||
| Q2 25 | 1.9% | 5.3% | ||
| Q1 25 | 1.3% | 3.3% | ||
| Q4 24 | 1.3% | 0.0% | ||
| Q3 24 | 3.2% | 2.3% | ||
| Q2 24 | 3.2% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 4.10× | ||
| Q3 25 | 1.66× | 1.00× | ||
| Q2 25 | 8.87× | 1.94× | ||
| Q1 25 | 2.23× | 1.53× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.46× | ||
| Q2 24 | — | 1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
GLPI
Segment breakdown not available.
